Bio-Bridge Science Announces Increase of $1.45 Million to Private Placement

  
    
  
  
    
      Bio-Bridge Science, Inc. (OTCBB:BGES), 
      a biotechnology company engaged in the commercial development of 
      vaccines for the prevention and treatment of human infectious diseases 
      announced today that it had increased the size of its private placement 
      by closing a sale of additional investment units. Each investment unit 
      consists of a share of common stock, two series of common stock purchase 
      warrants to purchase 0.5 share of common stock respectively. The 
      offering of $1,450,000 of investment units was purchased by a director, 
      Mr. Cheung Hin Shun Anthony.
    
    
      The Company will receive total proceeds of $ 1.45 million. $120,000 was 
      paid at closing, and the balance of $1.33 million will be paid in ten 
      equal amounts in monthly installments until May 31, 2009. The proceeds 
      will be used for general working capital purpose and to fund our vaccine 
      development activities in China.
    
    
      Dr. Liang Qiao, Chairman and CEO of Bio-Bridge said, “We 
      are happy to see our directors show a strong support for our company and 
      have confidence in our business and strategy. We closed private 
      placements for a total $4.23 million recently, including Mr. Cheung’s 
      investment. We expect that these funds will assist us in both our core 
      business of vaccine development and in plans for our acquisitions/joint 
      ventures. We are optimistic that our continuous hard work will begin to 
      demonstrate results.”
    
    
      This press release contains forward-looking statements. Forward-looking 
      statements include statements concerning plans, objectives, goals, 
      strategies, future events or performance, and underlying assumptions and 
      other statements that are other than statements of historical facts. 
      These statements are subject to uncertainties and risks including, but 
      not limited to, product and service demand and acceptance, changes in 
      technology, economic conditions, the impact of competition and pricing, 
      government regulation, and other risks defined in this document and in 
      statements filed from time to time with the Securities and Exchange 
      Commission. All such forward-looking statements, whether written or 
      oral, and whether made by or on behalf of the company, are expressly 
      qualified by these cautionary statements and any other cautionary 
      statements which may accompany the forward-looking statements. In 
      addition, the company disclaims any obligation to update any 
      forward-looking statements to reflect events or circumstances after the 
      date hereof. Please refer to the Company's SEC filings for additional 
      information.